Minimal peptide fusions for targeted intracellular protein degradation
AssigneeMassachusetts Institute of Technology
InventorsPranam CHATTERJEE, Joseph M. JACOBSON
Life of this patent
Estimating the term…
Abstract
Methods and compositions relating to an engineered peptide capable of binding to an infectious biological molecule for inhibition by mediated degradation using the ubiquitin proteasome pathway. The engineered peptide includes a targeting domain and an ubiquitin ligase recruiting domain. The engineered peptide includes a targeting domain and an ubiquitin ligase. The targeting domain is computationally-derived from a known receptor for the infectious biological molecule. The engineered peptide is optimized for minimal size and minimum off-target effects.
Claims20
An engineered peptide for mediated degradation of a target infectious microbe, comprising:
- a fusion protein comprising a targeting domain and a ubiquitin ligase recruiting domain;
- wherein the targeting domain is engineered to bind the target infectious microbe for mediation degradation by the ubiquitin-proteosome pathway.
The engineered peptide of claim 15, wherein the E3 ubiquitin ligase is CHIPΔTPR, corresponding to SEQ. ID. 5.
A method for the treatment or alleviation of an infection by an infectious microbe in a subject comprising:
- administering to the subject an engineered peptide or pharmaceutically acceptable salt thereof, wherein the engineered peptide comprises a fusion of a targeting domain and a ubiquitin ligase recruiting domain;
- and
- wherein the targeting domain is engineered to bind the target infectious microbe for mediation degradation by the ubiquitin-proteosome pathway.
Dependencies are inferred from the claim text.